Sun Pharma, headquartered in Mumbai, India, was established in 1983 by Dilip Shanghvi. It is the largest specialty generic pharmaceutical company in India, with a market share of over 8%, and the fourth largest in the world.

Sun Pharma offers a diverse range of products, including branded generics, generics, specialty products, over-the-counter products, and active pharmaceutical ingredients. It operates in more than 100 countries across six continents and has over 40 manufacturing facilities.

Sun Pharmaceutical Industries Limited reported financials for the fourth quarter & full year ending March 31st, 2022. In the fiscal year 2022, Sun Pharmaceutical Industries generated a consolidated income of over 39.500 scores Indian rupee. The company has a market capitalization of about $23 billion as of May 2023 and has consistently delivered profitable growth for its shareholders. Sun Pharma has also made significant investments in research and development to bring innovative solutions for unmet medical needs. With several milestones achieved, Sun Pharma has proven to be a reliable and professional player in the pharmaceutical industry.

Sun Pharma has achieved several milestones in its development over the recent years, such as launching a novel therapy for dry eye disease, showing positive results for osteoarthritis and alopecia areata candidates, acquiring Ranbaxy Laboratories and Taro Pharmaceutical Industries, and partnering with global players like Merck & Co., AstraZeneca, and Novartis.

Foundation: 1983
Headquarters: Mumbai, Maharashtra
Website: https://sunpharma.com/

Serum Institute of India Private Limited, established by Dr. Cyrus Poonawalla in 1966, is a leading vaccine manufacturer in the world, with a remarkable production capacity by volume. Headquartered in Pune, India, the company is engaged in producing vaccines for a wide range of diseases, including polio, measles, tetanus, diphtheria, hepatitis B, and COVID-19. The company exports its products to more than 170 countries worldwide, generating a revenue of approximately INR 25,000 crores in 2022.

The company boasts a cutting-edge manufacturing facility that has the capacity to produce over 1.5 billion doses of vaccines annually. Additionally, the company's research and development center is dedicated to discovering new and improved vaccines for emerging and neglected diseases. The company is committed to providing affordable and accessible vaccines to all, especially to low- and middle-income countries.

In the global fight against COVID-19, Serum Institute of India Private Limited has played a crucial role, the company has shown its commitment to the well-being of humanity by producing vaccines that are essential in the fight against the pandemic. It has partnered with AstraZeneca, Novavax, and Codagenix to produce and distribute its COVID-19 vaccines under the brand names Covishield, Covovax, and Covigenix respectively. It has also donated millions of doses of Covishield to the COVAX facility, which aims to ensure equitable access to COVID-19 vaccines for all countries.

Foundation: 1966

Headquarters: Pune, Maharashtra

Website: https://www.seruminstitute.com/

Dr. Reddy's Laboratories Limited was established in 1984 by Dr. K. Anji Reddy, a visionary entrepreneur and scientist with a passion for making quality medicines accessible and affordable to everyone. Over the years, the company has evolved into a global enterprise, with research and development facilities, manufacturing plants, and a commercial presence worldwide. With its innovative and generic drugs, the company serves over half a billion patients in more than 40 countries. As of 2022, Dr. Reddy's Laboratories' revenue was roughly INR 20,000 crores.

The company's diverse product portfolio includes a range of therapy areas, such as gastroenterology, oncology, pain management, cardiovascular, dermatology, urology, nephrology, rheumatology, and diabetes. Dr. Reddy's Laboratories has also developed several biosimilars and complex generics that offer improved treatment options for patients. Some of the company’s flagship brands include Omez (omeprazole), Nise (nimesulide), Stamlo (amlodipine), Razo (rabeprazole), Ciprolet (ciprofloxacin), and Mintop (minoxidil).

Dr. Reddy’s Laboratories Limited is not only a maker of molecules but also a provider of medicines that go beyond the pill. The company has launched several initiatives under its Purple Health platform to address the unmet needs of patients and caregivers. These include disease awareness and convenient diagnosis programs, access to medicines schemes, better therapy experience solutions, and adherence to therapy support.

Foundation: 1984
Headquarters: Hyderabad, Telangana

Website: https://www.drreddys.com/

Intas Pharmaceuticals Limited, established in 1984 and based in Ahmedabad, Gujarat, is a global leader in the pharmaceutical industry. With over 10,000 product registrations in more than 85 countries worldwide, the company boasts an extensive portfolio spanning various key therapeutic segments, including CNS, cardiovascular, diabetology, gastroenterology, urology, oncology, hematology, immunology, and neurology. In addition, Intas Pharmaceuticals Limited has a diversified range of products, including biosimilars, nutraceuticals, animal health products, and plasma therapy products, catering to the needs of various markets. In 2022, Intas Pharmaceuticals Limited generated revenue of approximately INR 18,500 scores.

One of the company's standout features is its unwavering emphasis on research and development. The company has 17 advanced facilities with global regulatory authority accreditations, making it a pioneer in biosimilars. Some of its notable products include Terifrac (teriparatide), Pegasta (pegylated filgrastim), MabTas (rituximab), and Thymotas (thymoquinone).

Intas Pharmaceuticals Limited is also committed to social responsibility and corporate citizenship. It supports various initiatives in the areas of education, health care, environment, and community development. It has partnered with several NGOs and government agencies to provide quality health care to the underprivileged sections of society. It has also contributed to the fight against COVID-19 by developing plasma therapy products and a patented immuno-booster add-on to standard treatment.

Foundation: 1984

Headquarters: Ahmedabad, Gujarat
Website: https://www.intaspharma.com/

Lupin Limited, a multinational pharmaceutical company based in Mumbai, India, was established in 1968 by Dr. Desh Bandhu Gupta. Dr. Gupta's vision was to provide affordable and high-quality medicines to the masses, which has become the company's mission. Over the years, Lupin Limited has expanded globally, operating in more than 100 countries and offering a vast portfolio of 1,800 products across several therapeutic areas. The company is a leading manufacturer of anti-tuberculosis drugs and a frontrunner in cardiovascular, diabetes, asthma, and anti-infective medications. As of 2022, Lupin Limited's revenue was approximately INR 15,800 crores.

Lupin Limited's focus on research and development is evident in its 12 state-of-the-art facilities, employing more than 2,000 scientists across India, Japan, the US, and Europe. The company invests around 10% of its revenue in R&D annually, resulting in over 500 patents for its innovative products and processes. Lupin Limited is also committed to social responsibility and sustainability, with initiatives such as Lupin Human Welfare and Research Foundation, Lupin Foundation, and Lupin Research Park. Lupin Limited has received several awards and recognitions for its excellence in business, quality, ethics, and corporate governance.

Lupin Limited is a company that strives to make a difference in the lives of millions of people around the world by providing them with access to affordable and quality healthcare. Lupin Limited is a company that believes in innovation, integrity, and inclusiveness.

Foundation: 1968

Headquarters: Mumbai, Maharashtra
Website: https://www.lupin.com/

Zydus Lifesciences, established in 1952 by Mr. Ramanbhai B. Patel with the initial name Cadila Healthcare Limited, is a distinguished player in the Indian drug discovery industry. The company offers a wide range of products, including active pharmaceutical ingredients, formulations, animal healthcare products, and wellness products. Zydus Lifesciences has made significant breakthroughs in the treatment of lung cancer, tuberculosis, cardiovascular diseases, and gastroenterology. In the fiscal year 2022, the company earned approximately INR 15,700 crores in revenue.

Zydus Lifesciences aspires to become a leading global healthcare provider with a unique approach. The company's mission is to create healthier communities by providing affordable and accessible medicines and solutions. The organization's values are centered on excellence, integrity, teamwork, innovation, and customer focus. The company's brand promise is to be dedicated to life in all its dimensions.

The company has been recognized for its excellence and innovation by various national and international awards. Moreover, the company is also committed to its social responsibility through its CSR program, Zydus Srishti. The program covers four areas: health (Swasthya), education (Shiksha), research (Shodh), and outreach (Saath). Through these initiatives, the company aims to make a positive difference in the lives of the underprivileged and marginalized sections of society.

Foundation: 1952
Headquarters: Ahmedabad, Gujarat

Website: https://www.zyduscadila.com/

Biocon Limited is an esteemed biopharmaceutical company headquartered in Bengaluru, India. Established in 1978 by Dr. Kiran Mazumdar-Shaw, who presently serves as the executive chairperson of the organization. Biocon boasts of being one of the largest and most diversified biopharmaceutical companies in Asia and operates in over 120 countries worldwide. The company has four main business segments, namely generics, biosimilars, research services, and novel biologics. As of 2022, Biocon's revenue stood at around INR 7,000 crores, a testament to its profitability and success.

Biocon's generics segment offers a wide range of active pharmaceutical ingredients (APIs) and formulations for chronic therapies such as diabetes, oncology, immunology, and nephrology. Moreover, Biocon's research services business, Syngene International, is a reputable contract research organization that provides end-to-end discovery, development, and manufacturing services to global pharma, biotech, and specialty chemical companies. Lastly, Biocon's novel biologics business is dedicated to developing innovative therapies for unmet medical needs such as oral insulin, immuno-oncology, and anti-infectives, demonstrating its commitment to advancing the healthcare industry.

Biocon is committed to social responsibility and sustainability through its CSR arm, Biocon Foundation, which works in the areas of health, education, environment, and community development. Biocon Foundation also runs Biocon Academy, a center of excellence for advanced learning in applied biosciences. Biocon has been recognized as one of the world's most innovative companies by Forbes and as one of the best employers in India by Business Today. Biocon has over 12,000 employees across India and overseas offices in the USA, Europe, the Middle East, and Asia-Pacific.

Foundation: 1978
Headquarters: Bengaluru, Karnataka

Website: https://www.biocon.com/

Bharat Biotech International Limited, a biotechnology company based in Hyderabad, India, was established in 1996 by Krishna Ella. The company specializes in the production of vaccines and biotherapeutics, with a diverse range of products including vaccines for rotavirus, typhoid, and hepatitis B. In 2022, Bharat Biotech generated revenue of approximately INR 5,000 crores.

Bharat Biotech International Limited boasts a modern manufacturing facility equipped with biosafety level 3 (BSL3) laboratories. Over the years, the company has successfully manufactured more than 4 billion doses of vaccines for various diseases such as rabies, hepatitis B, typhoid, rotavirus, Japanese encephalitis, H1N1, diphtheria, tetanus, pertussis, Hib infections, polio, and chikungunya.

Furthermore, Bharat Biotech International Limited is the creator of COVAXIN®, India's first indigenous COVID-19 vaccine, which has been granted emergency use authorization by the Drugs Controller General of India (DCGI) and the World Health Organization (WHO). BBIL is also developing another COVID-19 vaccine called BBV154, which is being developed in collaboration with Precision Virologics and Washington University School of Medicine in St. Louis, Missouri.

Bharat Biotech International Limited is a research-led company that has been pursuing scientific breakthroughs and innovation for over 25 years. Furthermore, the company has also received several awards and recognitions for its contributions to biotechnology and public health.

Foundation: 1996

Headquarters: Hyderabad, Telangana
Website: https://www.bharatbiotech.com/

Wockhardt is an Indian pharmaceuticals company headquartered in Mumbai, India. It was founded in 1967 by Dr. Habil Khorakiwala and is primarily engaged in the manufacture of generic drugs and specialty pharmaceuticals. In 2022, Wockhardt’s revenue was approximately INR 3,500 crores.

Wockhardt Limited has a diversified portfolio of products, ranging from antibiotics, vaccines, biopharmaceuticals, generics, OTC products, and active pharmaceutical ingredients (APIs). The company has a strong focus on research and development (R&D), with over 600 scientists working in six state-of-the-art facilities. Wockhardt Limited has also established several collaborations and partnerships with global institutions and organizations, such as the World Health Organization (WHO), the Bill and Melinda Gates Foundation, the UK Department of Health, and the US Food and Drug Administration (FDA).

Wockhardt Limited's vision is to be a global leader in affordable and innovative healthcare solutions, with a mission to improve the quality of life of millions of people around the world. The company's core values are excellence, integrity, innovation, teamwork, and customer-centricity.

Wockhardt Limited is committed to social responsibility, sustainability and has undertaken various initiatives to support education, health, environment, and community development. Some of these initiatives include the Wockhardt Foundation, the Wockhardt Hospitals, the Wockhardt Institute of Aesthetics, and the Wockhardt Skills Development Centre.

Foundation: 1967
Headquarters: Mumbai, Maharashtra

Website: https://www.wockhardt.com/

Syngene was established in 1994 as a subsidiary of Biocon Limited, India's largest biopharmaceutical company. Since then, Syngene has grown to become one of the largest and most diversified contract research and manufacturing organizations in Asia, with over 4500 scientists and staff, and a state-of-the-art research campus spread over 200 acres in Bengaluru. In 2022, Syngene International’s revenue was approximately INR 3,000 crores.

Syngene's extensive range of capabilities encompasses various domains, including small molecule and biologics discovery and development, analytical and formulation development, clinical development, safety assessment, and custom synthesis and manufacturing. Additionally, Syngene has established specialized centers of excellence for therapeutic areas including oncology, immunology, ophthalmology, metabolic diseases, and infectious diseases.

Syngene prioritizes innovation and excellence in science, as evidenced by its impressive track record. The company has filed over 140 patents and published over 300 peer-reviewed papers in esteemed journals. Furthermore, Syngene has also received numerous awards and recognitions for its exceptional achievements in contract research and manufacturing.

Syngene is a publicly listed company on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE) since 2015. Syngene has a market capitalization of over $3 billion as of May 2023. Syngene's vision is to be a global leader in innovation-led scientific services that enable better health outcomes for patients worldwide.

Foundation: 1994

Headquarters: Bengaluru, Karnataka

Website: https://www.syngeneintl.com/